The Supreme Court has temporarily reinstated telehealth and mail access to the abortion pill mifepristone on Monday, responding to an emergency appeal that warned of potential chaos for patients who had appointments to access the drug.
The ruling is an administrative stay, meaning it maintains the status quo for a few days while the court reviews the emergency appeals filed on Saturday by the drug’s manufacturer, Danco Laboratories, and the maker of a generic version, GenBioPro.
This decision temporarily blocks a ruling from the 5th US Circuit Court of Appeals, which had reinstated a nationwide requirement that mifepristone be obtained in person.
This reversal undermines the accessibility of a widely used abortion method that has grown more prevalent following the Supreme Court’s decision to overturn Roe v. Wade.
Key Details of the Stay and Legal Appeals
The temporary order issued by Justice Samuel Alito remains in effect until May 11, and he has requested a response to the appeals by Thursday.
Danco Laboratories argued in its appeal that the 5th Circuit ruling would cause “immediate confusion and upheaval” for patients who urgently needed the medication.
Similarly, GenBioPro warned that the ruling could “abruptly cut off access for patients nationwide,” especially given the time-sensitive nature of abortion procedures.
This emergency case brings the issue of mifepristone and abortion back to the Supreme Court’s docket less than two years after the justices allowed the drug to remain widely available, even after similar challenges.
Alito, who handles emergency appeals originating from the 5th Circuit, will oversee this case.
Impact on Telehealth and Medication Abortion Access
Since the COVID-19 pandemic, mifepristone has been available through telehealth consultations, allowing women to access the drug without an in-person doctor’s visit.
In 2023, the Biden administration finalized rules that ended the in-person visit requirement for obtaining mifepristone, a decision made after the Supreme Court overturned Roe v. Wade.
Medication abortions have become increasingly common, especially as conservative states have banned or heavily restricted access to clinic abortions.
According to the Guttmacher Institute, medication abortions accounted for more than 60% of all abortions in the US in 2023.
A CNN analysis of mifepristone data shows that the drug is considered overwhelmingly safe, with fewer reported side effects than medications like Viagra or penicillin.
State Legal Battles and Future Challenges
Louisiana has been a key player in the ongoing legal disputes over mifepristone access.
Last year, Louisiana filed a lawsuit arguing that the Biden-era regulation, which allowed telehealth prescriptions, undermined the state’s abortion ban.
In April, a federal district court declined to restrict access to mifepristone until the FDA completed a safety review of the drug.
In response to the Supreme Court’s temporary stay, Louisiana Attorney General Liz Murrill criticized the decision, accusing “Big abortion pharma” of seeking the stay to increase profits by distributing the drug without proper medical oversight.
She expressed confidence that the law would ultimately prevail, stating, “I am confident life and the law will win in the end.”
The Supreme Court previously reviewed the issue in 2024 and unanimously rejected a lawsuit challenging the FDA’s regulation.
However, the decision was narrowly focused on the standing of the plaintiffs, meaning future challenges were likely to resurface before the justices.
The Supreme Court’s decision to temporarily restore access to mifepristone through telehealth and mail means that patients will not immediately lose access to this method of medication abortion.
As the court reviews emergency appeals, the legal battle over mifepristone’s availability continues, and its outcome will have significant implications for abortion access across the United States.
With ongoing legal challenges, the case is far from resolved, and the final decision could have a lasting impact on reproductive rights.
